Skip to main content

Table 1 Characteristics of the 15 studies

From: Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis

Author-year (study period) Country

Sample number

Sex

Median follow-up period (months)

Age: mean age or range

Histology

Histological type

TNM stage

Lymphatic endothelium markers

Males

Females

ADC

SCC

LCC

Others

Kitano-2017 (1988–2010) Japan [33]

89

64

25

range 10–153

< 60 y 25

≥60 y 64

NSCLC

53

36

0

0

II 40 III + IV 49

VEGFR-3

Nunomiya-2014 (2008–2011) Japan [25]

58

50

8

ND

71.3 y

NSCLC 40 SCLC 14 Others 4

ND

ND

ND

ND

I + II 20 III + IV 37

LYVE-1

Hao-2014 (2004–2012) China [34]

140

72

68

ND

≤65 y 56

> 65 y 84

NSCLC

36

39

28

4

I–IIIA

LYVE-1

Zhang-2012 (2003–2006) China [22]

65

38

27

ND

51.5 y

(range 32–76 y)

< 55 y 26

≥55 y 39

ADC

65

0

0

0

I + II 38 III + IV 27

D2–40

Dai-2011 (1999–2003) China [35]

98

ND

ND

37.53 ± 4.05

ND

NSCLC

59

39

0

0

ND

Podoplanin

Yamashita-2010 (1993–2000) Japan [36]

117

77

40

68.7

67.8 y (range 47–85 y)

< 68 y 67

≥68 y 50

Stage I NSCLC

78

31

6

2

IA 58 IB 59

VEGFR-3

Chen-2010 (1999–2001) China [37]

52

41

11

ND

51.9 y

(range 29–77 y)

< 60 y 31

≥60 y 21

NSCLC

16

23

0

13

I + II 33

III 19

LYVE-1

Sun-2009 (1995–2004) China [38]

82

63

19

ND

< 55 y 40

≥55 y 42

NSCLC

41

31

10

0

I + II 48

III + IV 34

D2–40

Iwakiri-2009 (1998–1990) Japan [39]

215

159

56

ND

63.0 y

(range 53–71.8 y)

< 63 y 109

≥63 y 106

NSCLC

116

82

10

7

I + II 147

IIIA 68

D2–40

Kitano-2009 (ND) Japan [23]

82

45

37

ND

65 y

ADC

82

0

0

0

I + II 65

III + IV 17

Podoplanin

Kadota-2008 (1998–2002) Japan [24]

147

100

47

ND

67 y

(range 35–82 y)

NSCLC

93

49

5

0

I + II 108

III 39

D2–40

Ohta-2006 (1981–2004) Japan [40]

44

23

21

20

64.4 y

NSCLC

25

17

0

2

IIIA 35

IIIB 9

D2–40

Kojima-2005 (1981–1998) Japan [26]

129

62

67

69.9

61 y

(range 38–78 y)

ADC

129

0

0

0

ND

VEGFR-3

Chen-2004 (1985–1990) Japan [41]

206

148

58

ND

< 64 y 101

≥64 y 105

NSCLC

116

75

10

5

I + II 144

IIIA 62

VEGFR-3

Arinaga-2003 (1990–1996) Japan [27]

180

133

47

54.6

65 y

(range 35–84 y)

NSCLC

65

101

0

14

I + II 130

III 41

VEGFR-3

  1. NSCLC non-small cell lung carcinoma, SCLC small cell lung carcinoma, ADC adenocarcinoma, SCC squamous cell cancer, LCC large cell cancer, VEGFR-3 vascular endothelial growth factor receptor-3, LYVE-1 lymphatic vessel endothelial receptor 1, y year, ND no data